pharma

Divi's Laboratories

DIVISLAB · Nifty 50

6,663.5

Price 2026-06-17

BROAD EXPANSION73% confidence

At a Glance

Sector Positionpharma sector. Flow: neutral. is not among current leaders. Regime: BROAD EXPANSION (73%).
Fundamental Score85/100 (STRONG). 1 positive flags, 2 concerns.
Historical Context153 similar technical setups. Average outcome: -9.6% decline. 0% positive.

Fundamental

85/100

STRONG

Trust

95/100

Verification

Coverage

44/100

LIMITED

Quick Take

Divi's Laboratories scores 85/100 on fundamentals (strong). Divi's Laboratories: BROAD EXPANSION regime.

Fundamental Score: 85/100 · STRONG · 1 signals detected

DuPont Analysis

ROE 15.2% broken into three drivers. Each shows how efficiently the company generates returns.

ROE15.2%=
24.4%Net Margin
×
0.5xTurnover
×
1.2xLeverage

ROE of 15.16% is moderate margin-driven and stable. Net margin of 24.4% × asset turnover of 0.52x × leverage of 1.2x.

What This Means

Net margin of 24.4% means the company keeps ₹24.4 as profit for every ₹100 of revenue. This is a healthy margin. Asset turnover of 0.52x means the company efficiently uses its assets to generate revenue. Leverage of 1.2x means the company uses moderate debt. Returns are primarily driven by operations, not borrowing.

Margin Structure

Gross

61.6%

Operating

32.2%

Net

24.4%

improving

Gross margin 61.6% → operating margin 32.2% → net margin 24.4%. Margins are IMPROVING. Strong pricing power with stable gross margins suggests the improvement is from operating leverage — sustainable.

Financial Health

Earnings Quality

ADEQUATE

Cash flow covers net income 1.1x — earnings are ADEQUATE quality. Cash conversion is reasonable.

Debt Sustainability

COMFORTABLE

Interest covered 209.8x — very comfortable. Debt service is not a concern.

Free Cash Flow

MODERATE

FCF margin at 2.1% — barely positive. Limited cash after capex.

Peer Comparison

Divi's Laboratories is compared against 10 peers in the pharma sector.

Key Watchpoints

🟢

Breaks above ₹6997 (+5%)

Trend reversal confirmation

🔴

Breaks below ₹6330 (-5%)

Further downside risk

🟢

Pharma sector entering leadership

Sector rotation signal

Detected Patterns

➡️ Leverage Slowly Rising: Debt growing faster (75.0%) than equity (12.0%)

Risk Flags

🔴 1 Critical⚠️ 1 Warning1 Positive3 total flags
🔴Cash covers only 6% of current liabilities
Balance Sheet

Liquidity squeeze. Company may struggle to meet short-term obligations without refinancing.

⚠️Price/Sales: 17.0x — expensive on revenue basis
Valuation

High revenue multiple. Market pricing in significant growth or margins expansion.

Minimal unusual items — clean earnings
Earnings Quality

Profits are from core operations, not one-offs. High quality.

⚠️ 1 critical + 1 warning flags. Exercise caution.

Data Quality

95/100All ratios self-computed from verified sources. 🟢 5 years of financial data — sufficient for trend analysis

News Correlation

margin pressure (4)management outlook (4)
⚠️ Our margin analysis (improving) contradicts news reports of margin pressure — investigate

50 articles scanned for fundamental themes

Facts

P/E Ratio
68.5UNAVAILABLE
P/B Ratio
10.5HIGH
Market Cap
₹17621804.6L CrHIGH
From 52W High
94% of high
Sector Peers
10
Divi's Laboratories Stock Analysis, Valuation, Fundamentals & Intelligence | FynSight